Enhanced erythropoiesis and iron metabolism
The present invention relates to methods and compounds for regulating or enhancing erythropoiesis and iron metabolism, and for treating or preventing iron deficiency and anemia of chronic disease.
1. A method of treating anemia in a human subject with kidney disease comprising administering to the human subject an effective amount of a compound of formula (I)
wherein
A is —CR5R6 and R5 and R6 are each hydrogen;
B is —CO2H;
X is 0;
Q is 0;
R4 is hydrogen
Y is CR3;
R1, R2 and R3 are identical or different and are hydrogen, halogen, (C1-C20)-alkyl, (C6-C12)-aryl, (C1-C20)-alkoxy, (C6-C12)-aryloxy, N-((C1-C18)-alkoxy-(C1-C10)-alkyl)-carbamoyl, or (C6-C12)-arylmercapto; where an aryl radical may be substituted by halogen;
or R1 and R2, or R2 and R3, together with the pyridine carrying them, form a heterocyclic ring systems selected from quinoline, having formula (Ia) and isoquinoline, having formula (Ib):
wherein the substituents R12 to R19 in each case independently of each other have the meaning of R1, R2 and R3;
including the physiologically active salts derived therefrom, wherein the anemia is treated.
2. The method of claim 1 , wherein the compound inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase enzyme activity.
3. The method of claim 1 , wherein the compound stabilizes the alpha subunit of hypoxia inducible factor.
4. The method of claim 1 , wherein the compound is orally administered to the human subject.
5. The method of claim 1 , wherein the human subject is undergoing kidney dialysis.
6. The method of claim 1 , wherein the human subject is not undergoing kidney dialysis.
7. The method of claim 1 , wherein the erythropoietin plasma level in the human subject is increased following administration of the effective amount of the compound.
8. The method of claim 1 , wherein the plasma hematocrit level in the human subject is increased following administration of the effective amount of the compound.
9. The method of claim 1 , wherein the plasma hemoglobin level in the human subject is increased following administration of the effective amount of the compound.
10. The method of claim 1 , wherein administration of the compound to the human subject reduces the need for the human subject to receive an allogenic blood transfusion.
11. The method of claim 1 further comprising administering exogenous erythropoietin to the human subject.
12. The method of claim 1 , wherein the kidney disease is chronic.
13. A method of treating anemia in a human subject with chronic renal failure comprising administering to the human subject an effective amount of a compound of formula (I)
wherein
A is —CR5R6 and R5 and R6 are each hydrogen;
B is —CO2H;
X is 0;
Q is 0;
R4 is hydrogen
Y is CR3;
R1, R2 and R3 are identical or different and are hydrogen, halogen, (C1-C20)-alkyl, (C6-C12)-aryl, (C1-C20)-alkoxy, (C6-C12)-aryloxy, N-((C1-C18)-alkoxy-(C1-C10)-alkyl)-carbamoyl, or (C6-C12)-arylmercapto; where an aryl radical may be substituted by halogen;
or R1 and R2, or R2 and R3, together with the pyridine carrying them, form a heterocyclic ring systems selected from quinoline, having formula (Ia) and isoquinoline, having formula (Ib):
wherein the substituents R12 to R19 in each case independently of each other have the meaning of R1, R2 and R3;
including the physiologically active salts derived therefrom, wherein the anemia is treated.
14. The method of claim 13 , wherein the compound inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase enzyme activity.
15. The method of claim 13 , wherein the compound stabilizes the alpha subunit of hypoxia inducible factor.
16. The method of claim 13 , wherein the compound is orally administered to the human subject.
17. The method of claim 13 , wherein the human subject is undergoing kidney dialysis.
18. The method of claim 13 , wherein the human subject is not undergoing kidney dialysis.
19. The method of claim 13 , wherein the erythropoietin plasma level in the human subject is increased following administration of the effective amount of the compound.
20. The method of claim 13 , wherein the plasma hematocrit level in the human subject is increased following administration of the effective amount of the compound.
21. The method of claim 13 , wherein the plasma hemoglobin level in the human subject is increased following administration of the effective amount of the compound.
22. The method of claim 13 , wherein administration of the compound to the human subject reduces the need for the human subject to receive an allogenic blood transfusion.
23. The method of claim 13 further comprising administering exogenous erythropoietin to the human subject.